Analyst picks & changes

Gensia Inc.


Richard Stover of Stover Haley Burns said he remains optimistic regarding the regulatory review of GNSA's Protara (Arasine), despite the company's announcement earlier this month that the FDA won't review the drug for reducing

Read the full 374 word article

How to gain access

Continue reading with a
two-week free trial.